In a phase Ib dose-escalation study, a highly selective pan-PI3K inhibitor, buparlisib, in combination with the MEK1/2 inhibitor trametinib, represented promising anti-tumor activity in patients with KRAS-mutant ovarian cancer; however, it should be noted that the combination required dose modifications and interruptions due to the toxicity [182]. This evidence concerns the gene PIK3CA and neoplasm.